South Grafton, MA, United States of America

Dingxue Yan

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Dingxue Yan: Advancements in Macrocyclic Compounds

Introduction: Dingxue Yan, based in South Grafton, Massachusetts, is an accomplished inventor with a notable contribution to the field of medicinal chemistry. With a focus on macrocyclic compounds, Yan's work holds promise for the treatment of inflammatory diseases and IL-17-associated disorders.

Latest Patents: Yan holds a patent titled "Macrocyclic compounds for modulating IL-17". This invention encompasses macrocyclic compounds that are designed to modulate the activity of IL-17, a key player in various inflammatory responses. The therapeutic applications of these compounds signify a potential breakthrough in managing conditions linked to IL-17.

Career Highlights: As part of Ensemble Therapeutics Corporation, Yan has made strides in research and development, particularly in the design and application of therapeutic compounds. His work showcases the intersection of scientific research and practical pharmaceutical applications, providing avenues for future innovations in treatment modalities.

Collaborations: Throughout his career, Dingxue Yan has collaborated with esteemed colleagues such as Michael Taylor and Nicholas K Terrett. These collaborations foster a dynamic environment for innovation and enhance the development of cutting-edge therapeutic solutions.

Conclusion: Dingxue Yan's contributions to the field of medicinal chemistry through his patent on macrocyclic compounds mark him as a key player in the ongoing battle against inflammatory diseases. As his research progresses, the implications of his work may lead to improved treatment options and a better understanding of IL-17-related disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…